Christophe Champion

Christophe Champion

Auto-generated profile, based on publicly available information

Christophe Champion

Laboratoire de Physique Moléculaire et des Collisions, ICPMB (FR CNRS 2843), Institut de Physique, Université Paul Verlaine-Metz, Metz cedex 3, France

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2020 in EJNMMI Physics
Verified
Journal Article
Open access
PDF file
MAMario E. Alcocer-Ávila
Mario E. Alcocer-Ávila
AFAymeric Ferreira
Aymeric Ferreira
MQMichele A. Quinto
Michele A. Quinto
CMClément Morgat
Clément Morgat
Elif HindiéElif Hindié
Elif Hindié
CCChristophe Champion
Christophe Champion
Background: Targeted radionuclide therapy (TRT) is gaining importance. For TRT to be also used as adjuvant therapy or for treating minimal residual disease, there is a need to increase the radiation dose to small tumours. The aim of this in silico study was to compare the performances of 161Tb (a medium-energy β− emitter with additional Auger and conversion electron emissions) and 177Lu for irradiating single tumour cells and micrometastases, with various distributions of the radionuclide. Methods: We used the Monte Carlo track-structure (MCTS) code CELLDOSE to compute the radiation doses delivered by 161Tb and 177Lu to single cells (14 μm cell diameter with 10 μm nucleus diameter) and to a tumour cluster consisting of a central cell surrounded by two layers of cells (18 neighbours). We focused the analysis on the absorbed dose to the nucleus of the single tumoral cell and to the nuclei of the cells in the cluster. For both radionuclides, the simulations were run assuming that 1 MeV was released per μm3 (1436 MeV/cell). We considered various distributions of the radionuclides: either at the cell surface, intracytoplasmic or intranuclear. Results: For the single cell, the dose to the nucleus was substantially higher with 161Tb compared to 177Lu, regardless of the radionuclide distribution: 5.0 Gy vs. 1.9 Gy in the case of cell surface distribution; 8.3 Gy vs. 3.0 Gy for intracytoplasmic distribution; and 38.6 Gy vs. 10.7 Gy for intranuclear location. With the addition of the neighbouring cells, the radiation doses increased, but remained consistently higher for 161Tb compared to 177Lu. For example, the dose to the nucleus of the central cell of the cluster was 15.1 Gy for 161Tb and 7.2 Gy for 177Lu in the case of cell surface distribution of the radionuclide, 17.9 Gy for 161Tb and 8.3 Gy for 177Lu for intracytoplasmic distribution and 47.8 Gy for 161Tb and 15.7 Gy for 177Lu in the case of intranuclear location. Conclusion: 161Tb should be a better candidate than 177Lu for irradiating single tumour cells and micrometastases, regardless of the radionuclide distribution.

15 June 2023 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
ALAlexandre Larouze
Alexandre Larouze
MAMario Alcocer-Ávila
Mario Alcocer-Ávila
CMClément Morgat
Clément Morgat
CCChristophe Champion
Christophe Champion
Elif HindiéElif Hindié
Elif Hindié
Early use of targeted radionuclide therapy to eradicate tumor cell clusters and micrometastases might offer cure. However, there is a need to select appropriate radionuclides and assess the potential impact of heterogeneous targeting. Methods: The Monte Carlo code CELLDOSE was used to assess membrane and nuclear absorbed doses from 177Lu and 161Tb (β−-emitter with additional conversion and Auger electrons) in a cluster of 19 cells (14-μm diameter, 10-μm nucleus). The radionuclide distributions considered were cell surface, intracytoplasmic, or intranuclear, with 1,436 MeV released per labeled cell. To model heterogeneous targeting, 4 of the 19 cells were unlabeled, their position being stochastically determined. We simulated situations of single targeting, as well as dual targeting, with the 2 radiopharmaceuticals aiming at different targets. Results:161Tb delivered 2- to 6-fold higher absorbed doses to cell membranes and 2- to 3-fold higher nuclear doses than 177Lu. When all 19 cells were targeted, membrane and nuclear absorbed doses were dependent mainly on radionuclide location. With cell surface location, membrane absorbed doses were substantially higher than nuclear absorbed doses, both with 177Lu (38–41 vs. 4.7–7.2 Gy) and with 161Tb (237–244 vs. 9.8–15.1 Gy). However, when 4 cells were not targeted by the cell surface radiopharmaceutical, the membranes of these cells received on average only 9.6% of the 177Lu absorbed dose and 2.9% of the 161Tb dose, compared with a cluster with uniform cell targeting, whereas the impact on nuclear absorbed doses was moderate. With an intranuclear radionuclide location, the nuclei of unlabeled cells received only 17% of the 177Lu absorbed dose and 10.8% of the 161Tb dose, compared with situations with uniform targeting. With an intracytoplasmic location, nuclear and membrane absorbed doses to unlabeled cells were one half to one quarter those obtained with uniform targeting, both for 177Lu and for 161Tb. Dual targeting was beneficial in minimizing absorbed dose heterogeneities. Conclusion: To eradicate tumor cell clusters, 161Tb may be a better candidate than 177Lu. Heterogeneous cell targeting can lead to substantial heterogeneities in absorbed doses. Dual targeting was helpful in reducing dose heterogeneity and should be explored in preclinical and clinical studies. Visual Abstract

1 October 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MAMario E. Alcocer-Ávila
Mario E. Alcocer-Ávila
Michele Arcangelo QuintoMichele Arcangelo Quinto
Michele Arcangelo Quinto
Juan MontiJuan Monti
Juan Monti
RRRoberto D. Rivarola
Roberto D. Rivarola
CCChristophe Champion
Christophe Champion
Whether it is in radiobiology to identify DNA lesions or in medicine to adapt the radiotherapeutic protocols, a detailed understanding of the radiation-induced interactions in living matter is required. Monte Carlo track-structure codes have been successfully developed to describe these interactions and predict the radiation-induced energy deposits at the nanoscale level in the medium of interest. In this work, the quantum-mechanically based Monte Carlo track-structure code TILDA-V has been used to compute the slowing-down of protons in water and DNA. Stopping power and range are then reported and compared with existing data. Then, a first application of TILDA-V to cellular irradiations is also reported in order to highlight the absolute necessity of taking into account a realistic description of the cellular environment in microdosimetry.

1 January 2024 in Theranostics
Verified
Journal Article
Open access
PDF file
Elif HindiéElif Hindié
Elif Hindié
ALAlexandre Larouze
Alexandre Larouze
MAMario Alcocer-Ávila
Mario Alcocer-Ávila
CMClément Morgat
Clément Morgat
CCChristophe Champion
Christophe Champion
Early use of targeted radionuclide therapy (TRT) to eradicate disseminated tumor cells (DTCs) might offer cure. Selection of appropriate radionuclides is required. This work highlights the potential of 103Pd (T1/2 = 16.991 d) which decays to 103mRh (T1/2 = 56.12 min) then to stable 103Rh with emission of Auger and conversion electrons.

10 April 2014 in Journal of Physics: Conference Series
Verified
Conference Paper
Open access
CCC Champion
C Champion
Mariel Elisa GalassiMariel Elisa Galassi
Mariel Elisa Galassi
PWP F Weck
P F Weck
CAC Abdallah
C Abdallah
ZFZ Francis
Z Francis
AIA Itoh
A Itoh

21 June 2018 in The European Physical Journal D
Verified
Journal Article
Closed access
PDF file
DODahbia Oubaziz
Dahbia Oubaziz
RBRachida Boulifa
Rachida Boulifa
ZAZakia Aitelhadjali
Zakia Aitelhadjali
CCChristophe Champion
Christophe Champion